Oral Azacitidine Matches Injection Exposure in MDS Study

Company Taiho Oncology; Taiho Pharmaceutical Event Type Detailed Phase 3 pharmacokinetic data Modality Small molecule (oral hypomethylating agent) Asset ASTX030 (azacitidine plus cedazuridine) Target DNA methyltransferase; cytidine deaminase Disease Area MDS and CMML Summary Taiho reported detailed AZTOUND data on November 4 after a September…